<DOC>
	<DOCNO>NCT00320801</DOCNO>
	<brief_summary>The original objective study demonstrate effectiveness tolerability buprenorphine transdermal system ( BTDS ) 20 microgram ( mcg ) /hour ( h ) comparison buprenorphine transdermal system 5 mcg/h subject moderate severe osteoarthritis pain currently treat oral opioids . The double-blind treatment intervention duration 12 week time supplemental analgesic medication ( acetaminophen ibuprofen ) provide subject addition study drug . This study terminate early due administrative reason 20 % plan sample size ; therefore , primary objective change focus safety evaluation .</brief_summary>
	<brief_title>Buprenorphine Transdermal Patches ( BTDS ) Subjects With Osteoarthritis Pain . Includes 52-week Extension Phase .</brief_title>
	<detailed_description>Buprenorphine synthetic opioid analgesic 25 year international clinical experience indicate safe effective variety therapeutic situation relief moderate severe pain .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>osteoarthritis hip , knee , spine 1 year longer . take 3080 milligram ( mg ) oral morphine sulfate equivalent/day , least 4 day week . take 80 mg per day oral morphine sulfate equivalent within 30 day enrollment . require frequent analgesic therapy chronic condition addition osteoarthritis . Other protocolspecific exclusion/inclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Chronic pain</keyword>
	<keyword>osteoarthritis</keyword>
	<keyword>transdermal</keyword>
</DOC>